Pathogenic considerations in sporadic inclusion-body myositis, a degenerative muscle disease associated with aging and abnormalities of myoproteostasis.
about
Idiopathic Inflammatory Myopathies: Clinical Approach and ManagementScanning for Therapeutic Targets within the Cytokine Network of Idiopathic Inflammatory MyopathiesMuscle biopsy features of idiopathic inflammatory myopathies and differential diagnosisThe protein oxidation repair enzyme methionine sulfoxide reductase a modulates Aβ aggregation and toxicity in vivo.Expression of FSHD-related DUX4-FL alters proteostasis and induces TDP-43 aggregationActivation of the Unfolded Protein Response in Sporadic Inclusion-Body Myositis but Not in Hereditary GNE Inclusion-Body Myopathy.Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM.Effects of long-term resistance exercise training on autophagy in rat skeletal muscle of chloroquine-induced sporadic inclusion body myositis.Compartment-dependent mitochondrial alterations in experimental ALS, the effects of mitophagy and mitochondriogenesisDisease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases.Demographic and clinical features of inclusion body myositis in North America.Mitochondrial dysfunction in myofibrillar myopathy.Nuclear bodies reorganize during myogenesis in vitro and are differentially disrupted by expression of FSHD-associated DUX4.Comparative utility of LC3, p62 and TDP-43 immunohistochemistry in differentiation of inclusion body myositis from polymyositis and related inflammatory myopathies.Proteins that accumulate with age in human skeletal-muscle aggregates contribute to declines in muscle mass and function in Caenorhabditis elegansDiagnosis, pathogenesis and treatment of myositis: recent advances.Inclusion body myositis: from immunopathology and degenerative mechanisms to treatment perspectives.Mechanistic effects of IVIg in neuroinflammatory diseases: conclusions based on clinicopathologic correlations.Cytokines in immune-mediated inflammatory myopathies: cellular sources, multiple actions and therapeutic implications.Idiopathic inflammatory myopathies: from immunopathogenesis to new therapeutic targets.Asymptomatic hyper-creatine-kinase-emia as sole manifestation of inclusion body myositis.[New aspects on the pathogenesis of myositis].Chaperone-mediated autophagy components are upregulated in sporadic inclusion-body myositis muscle fibres.Dysferlin is a newly identified binding partner of AβPP and it co-aggregates with amyloid-β42 within sporadic inclusion-body myositis (s-IBM) muscle fibers.Age-Related Changes in Skeletal Muscle of Cattle.
P2860
Q26744705-50A5235B-10AE-4AF1-9A93-6FC2546B9B18Q26798209-20B53DA8-B067-49B7-8A2D-6E3FB5797FBEQ26991722-88DBA949-FB36-4F5C-A159-51E11AEAA897Q34729853-EC12C7D9-9C7B-4683-9EAA-19172282E3DFQ35115914-DFEC4F66-8B21-419B-B04E-7050149052E6Q35864781-A53C0F35-256A-4864-8202-7E9240B694A6Q35991443-D788BE97-C87A-4DC9-B144-EDA4B656151BQ36218623-ED0B8386-B3E7-4B30-81C4-90751355C3A2Q36254308-010C1171-CDC4-40DF-8649-467B22197327Q36424500-053EB883-A52A-4B94-997B-9BC81E74D000Q36906852-EA202EEE-35C2-4FCE-87FB-8210FBC23644Q37343276-E3A4BC61-8D6A-44E5-814B-3E52D215E527Q37466448-26F1BF3B-F413-4D4B-B2D0-C3DC1E7DAB99Q37485423-E3F3EEF0-64EB-4CB7-A397-6A4B984D335BQ37610211-45F19107-C196-4F67-AE04-89703DD56F15Q38131849-1F35F910-F137-41FF-917B-05A9AAE20178Q38153797-27731A84-D255-4C8B-AFEB-6BB6B0C0BA0DQ38203801-ADB7D645-B8EF-4595-A93D-B64DD41E7227Q38244567-8AE624AB-7D8D-4A8B-9535-9E30C3F449B9Q38589301-4AFAC13A-721D-4545-85BF-5273CC4A158BQ42257194-358C4CBC-7A25-4131-942D-D3406F811A12Q43978656-6628AD5A-0412-42E8-ADF8-11F008BD97A6Q45328567-F4AD3AD0-991E-43B6-A2CE-CA79113EDF6AQ46388851-5BBF9296-0C82-4122-BF48-5959AF183F49Q50260921-C60A613B-12AA-48ED-9107-1B5EBBAD2A00
P2860
Pathogenic considerations in sporadic inclusion-body myositis, a degenerative muscle disease associated with aging and abnormalities of myoproteostasis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Pathogenic considerations in s ...... ormalities of myoproteostasis.
@en
type
label
Pathogenic considerations in s ...... ormalities of myoproteostasis.
@en
prefLabel
Pathogenic considerations in s ...... ormalities of myoproteostasis.
@en
P2093
P1476
Pathogenic considerations in s ...... ormalities of myoproteostasis.
@en
P2093
Anna Nogalska
Valerie Askanas
W King Engel
P304
P356
10.1097/NEN.0B013E31826183C8
P577
2012-08-01T00:00:00Z